All patent grants under the A61K category in India (2009-2016).

For further notes on methodology, as well as to see our analysis of the data, please see the corresponding report under the 'Arguments' tab: Pharmaceutical Patent Grants in India: How our safeguards against evergreening have failed, and why the system must be reformed.

Pharmaceutical patent grants in India (2009-2016) under analysis; these applications cover all traditional pharmaceutical patent grants in the period, with the exclusion of biologics.

For further notes on methodology, as well as to see our analysis of the data, please see the corresponding report under the 'Arguments' tab: Pharmaceutical Patent Grants in India: How our safeguards against evergreening have failed, and why the system must be reformed.

Pharmaceutical patent grants in India (2009-2016) which relate to biologics, an emerging class of drugs.

For further notes on methodology, as well as to see our analysis of the data, please see the corresponding report under the 'Arguments' tab: Pharmaceutical Patent Grants in India: How our safeguards against evergreening have failed, and why the system must be reformed.

Pharmaceutical patent grants in India (2009-2016) which relate to process claims.

For further notes on methodology, as well as to see our analysis of the data, please see the corresponding report under the 'Arguments' tab: Pharmaceutical Patent Grants in India: How our safeguards against evergreening have failed, and why the system must be reformed.

A61K patent grants in India (2009-2016) which do not relate to pharmaceuticals, comprising herbal medicines (302), cosmetics (233), dental products (70), and other unrelated categories (265).

For further notes on methodology, as well as to see our analysis of the data, please see the corresponding report under the 'Arguments' tab: Pharmaceutical Patent Grants in India: How our safeguards against evergreening have failed, and why the system must be reformed.